QQQ   284.33 (+0.19%)
AAPL   116.35 (+0.32%)
MSFT   214.74 (+0.24%)
FB   264.58 (+1.22%)
GOOGL   1,537.11 (+0.47%)
AMZN   3,206.44 (-0.02%)
TSLA   423.33 (-1.74%)
NVDA   542.58 (+0.49%)
BABA   308.65 (+1.10%)
CGC   18.92 (-4.49%)
GE   7.37 (+1.10%)
MU   53.44 (+1.54%)
AMD   81.25 (-0.91%)
T   26.84 (-0.15%)
F   7.78 (+2.50%)
ACB   4.34 (-7.86%)
GILD   60.22 (-0.58%)
NFLX   524.62 (-1.15%)
BA   167.94 (+0.50%)
BAC   24.16 (+1.85%)
DIS   124.18 (-0.04%)
QQQ   284.33 (+0.19%)
AAPL   116.35 (+0.32%)
MSFT   214.74 (+0.24%)
FB   264.58 (+1.22%)
GOOGL   1,537.11 (+0.47%)
AMZN   3,206.44 (-0.02%)
TSLA   423.33 (-1.74%)
NVDA   542.58 (+0.49%)
BABA   308.65 (+1.10%)
CGC   18.92 (-4.49%)
GE   7.37 (+1.10%)
MU   53.44 (+1.54%)
AMD   81.25 (-0.91%)
T   26.84 (-0.15%)
F   7.78 (+2.50%)
ACB   4.34 (-7.86%)
GILD   60.22 (-0.58%)
NFLX   524.62 (-1.15%)
BA   167.94 (+0.50%)
BAC   24.16 (+1.85%)
DIS   124.18 (-0.04%)
QQQ   284.33 (+0.19%)
AAPL   116.35 (+0.32%)
MSFT   214.74 (+0.24%)
FB   264.58 (+1.22%)
GOOGL   1,537.11 (+0.47%)
AMZN   3,206.44 (-0.02%)
TSLA   423.33 (-1.74%)
NVDA   542.58 (+0.49%)
BABA   308.65 (+1.10%)
CGC   18.92 (-4.49%)
GE   7.37 (+1.10%)
MU   53.44 (+1.54%)
AMD   81.25 (-0.91%)
T   26.84 (-0.15%)
F   7.78 (+2.50%)
ACB   4.34 (-7.86%)
GILD   60.22 (-0.58%)
NFLX   524.62 (-1.15%)
BA   167.94 (+0.50%)
BAC   24.16 (+1.85%)
DIS   124.18 (-0.04%)
QQQ   284.33 (+0.19%)
AAPL   116.35 (+0.32%)
MSFT   214.74 (+0.24%)
FB   264.58 (+1.22%)
GOOGL   1,537.11 (+0.47%)
AMZN   3,206.44 (-0.02%)
TSLA   423.33 (-1.74%)
NVDA   542.58 (+0.49%)
BABA   308.65 (+1.10%)
CGC   18.92 (-4.49%)
GE   7.37 (+1.10%)
MU   53.44 (+1.54%)
AMD   81.25 (-0.91%)
T   26.84 (-0.15%)
F   7.78 (+2.50%)
ACB   4.34 (-7.86%)
GILD   60.22 (-0.58%)
NFLX   524.62 (-1.15%)
BA   167.94 (+0.50%)
BAC   24.16 (+1.85%)
DIS   124.18 (-0.04%)
Log in
NASDAQ:INO

Inovio Pharmaceuticals Stock Forecast, Price & News

$10.60
-0.75 (-6.61 %)
(As of 10/20/2020 10:53 AM ET)
Add
Compare
Today's Range
$10.58
Now: $10.60
$11.47
50-Day Range
$9.57
MA: $12.69
$18.52
52-Week Range
$2.09
Now: $10.60
$33.79
Volume103,579 shs
Average Volume29.49 million shs
Market Capitalization$1.78 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.02
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Read More
Inovio Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.1Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.04 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INO
CUSIPN/A
Phone858-410-3134
Employees190

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.11 million
Book Value$0.05 per share

Profitability

Net Income$-119,360,000.00
Net Margins-8,099.02%

Miscellaneous

Market Cap$1.78 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$10.60
-0.75 (-6.61 %)
(As of 10/20/2020 10:53 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INO News and Ratings via Email

Sign-up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions

How has Inovio Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Inovio Pharmaceuticals' stock was trading at $8.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INO shares have increased by 28.7% and is now trading at $10.77.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Inovio Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Inovio Pharmaceuticals
.

When is Inovio Pharmaceuticals' next earnings date?

Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Inovio Pharmaceuticals
.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) issued its quarterly earnings data on Monday, August, 10th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.66. The biopharmaceutical company had revenue of $0.20 million for the quarter, compared to analysts' expectations of $2.61 million. Inovio Pharmaceuticals had a negative net margin of 8,099.02% and a negative return on equity of 120.41%. The firm's revenue was up 100.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.30) earnings per share.
View Inovio Pharmaceuticals' earnings history
.

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Shares of Inovio Pharmaceuticals reverse split before market open on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for INO?

9 equities research analysts have issued 1-year target prices for Inovio Pharmaceuticals' stock. Their forecasts range from $7.00 to $20.00. On average, they anticipate Inovio Pharmaceuticals' stock price to reach $12.00 in the next year. This suggests a possible upside of 11.4% from the stock's current price.
View analysts' price targets for Inovio Pharmaceuticals
.

Has Inovio Pharmaceuticals been receiving favorable news coverage?

Media headlines about INO stock have been trending very negative on Tuesday, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Inovio Pharmaceuticals earned a coverage optimism score of -3.8 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days.
View the latest news about Inovio Pharmaceuticals
.

Who are some of Inovio Pharmaceuticals' key competitors?

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the following people:
  • Dr. J. Joseph Kim, CEO, Pres & Director (Age 51, Pay $1.31M)
  • Mr. Peter D. Kies, Chief Financial Officer (Age 57, Pay $711.13k)
  • Dr. Jacqueline E. Shea Ph.D., Chief Operating Officer (Age 54, Pay $611.75k)
  • Dr. Laurent M. Humeau, Chief Scientific Officer (Age 53, Pay $572.16k)
  • Ben Matone, Director of Investor Relations
  • Mr. Jeffrey C. Richardson, VP of Communications & Strategic Relations
  • Mr. E. J. Brandreth, Sr. VP of Quality Assurance
  • Ms. Jessica C. Lee MS, MPH, Sr. VP of Clinical Operations & Global Integration
  • Dr. Ami Shah Brown, Sr. VP of Regulatory Affairs
  • Mr. Stephen Kemmerrer, Sr. VP of Engineering Devel.

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Avantax Advisory Services Inc. (0.01%), Investors Financial Group LLC (0.01%) and Pacer Advisors Inc. (0.00%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Laurent Humeau and Peter Kies.
View institutional ownership trends for Inovio Pharmaceuticals
.

Which major investors are buying Inovio Pharmaceuticals stock?

INO stock was purchased by a variety of institutional investors in the last quarter, including Avantax Advisory Services Inc., Investors Financial Group LLC, and Pacer Advisors Inc.. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Jong Joseph Kim, and Laurent Humeau.
View insider buying and selling activity for Inovio Pharmaceuticals
.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $10.77.

How big of a company is Inovio Pharmaceuticals?

Inovio Pharmaceuticals has a market capitalization of $1.80 billion and generates $4.11 million in revenue each year. The biopharmaceutical company earns $-119,360,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Inovio Pharmaceuticals employs 190 workers across the globe.

What is Inovio Pharmaceuticals' official website?

The official website for Inovio Pharmaceuticals is www.inovio.com.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 858-410-3134 or via email at [email protected]

This page was last updated on 10/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.